In a clinical trial of semaglutide injection for weight loss (Wegovy) in patients with T2DM and a BMI of 27 kg/m2 or more, hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of semaglutide-treated patients versus 2.5% of placebo-treated patients
MGDs have drug-like properties, induce TPD at low compound concentrations by acting catalytically, do not require preexisting ligands for both recruited proteins and can recruit partners without drug-binding pockets 1,7,8
[DOI] [PMC free article] [PubMed] [Google Scholar] Ishak N.S.M., Ikemoto K., Kikuchi M., Ogawa M., Akutagawa K., Akagawa M
any other use is strictly prohibited by law
References Bergmann, N
Different bottleneck priorities and ratios